Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform

Oppenheimer analyst Jay Olson upgraded Dyne Therapeutics (NASDAQ: DYN) from Perform to Outperform with a price target of $40.00 (from $11.00).

For an analyst ratings summary and ratings history on Dyne Therapeutics click here. For more ratings news on Dyne Therapeutics click here.

Shares of Dyne Therapeutics closed at $18.45 yesterday.

You May Also Be Interested In

• Morgan Stanley Upgrades Ivanhoe Mines Ltd. (IVN:CN) (IVPAF) to Overweight
• JPMorgan Upgrades Wanhua Chemical Group (600309:CH) to Overweight
• BNP Paribas Exane Upgrades Commercial Metals Company (CMC) to Outperform